Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Daiichi Sankyo
Biotech
ESMO: Daiichi, Merck move ovarian cancer ADC toward pivotal test
The partners saw a 50.5% response rate in a study that informed the selection of their phase 3 dose.
Nick Paul Taylor
Oct 20, 2025 10:45am
Daiichi, Merck rev up for accelerated approval filing
Sep 7, 2025 10:45am
Daiichi, Merck pull HER3-DXd filing at FDA
May 29, 2025 9:40am
Roche nets FDA breakthrough label for AI lung cancer CDx test
Apr 29, 2025 2:07pm
Daiichi taps Nosis to deliver RNA therapies beyond the liver
Mar 11, 2025 10:24am
J&J vet jumps to Affinia—Chutes & Ladders
Feb 7, 2025 8:30am
